<p>Sanofi's chief in France, Olivier Bogillot, said on Saturday that its future Covid-19 vaccine was likely to be priced below 10 euros per shot.</p>.<p>"The price is not totally set ... We are assessing production costs for the coming months ... We will be below 10 euros," Bogillot told France Inter radio.</p>.<p>Drugmakers and government agencies worldwide are racing to combat the pandemic and develop vaccines and treatments for Covid-19.</p>.<p>Asked about rival AstraZeneca, which is expected to price its shot at about 2.50 euros in Europe, Bogillot said:</p>.<p>"The price gap for us can be that we use all our internal resources, our own researchers, our own research centres. AstraZeneca outsources part of its production,"</p>.<p>Earlier this week Sanofi and Britain's GlaxoSmithKline said they had started a clinical trial of their protein-based Covid-19 vaccine candidate, and aimed to reach the final testing stage by December.</p>.<p>If the results are conclusive, Sanofi and GSK hope to get the vaccine approved in the first half of next year.</p>
<p>Sanofi's chief in France, Olivier Bogillot, said on Saturday that its future Covid-19 vaccine was likely to be priced below 10 euros per shot.</p>.<p>"The price is not totally set ... We are assessing production costs for the coming months ... We will be below 10 euros," Bogillot told France Inter radio.</p>.<p>Drugmakers and government agencies worldwide are racing to combat the pandemic and develop vaccines and treatments for Covid-19.</p>.<p>Asked about rival AstraZeneca, which is expected to price its shot at about 2.50 euros in Europe, Bogillot said:</p>.<p>"The price gap for us can be that we use all our internal resources, our own researchers, our own research centres. AstraZeneca outsources part of its production,"</p>.<p>Earlier this week Sanofi and Britain's GlaxoSmithKline said they had started a clinical trial of their protein-based Covid-19 vaccine candidate, and aimed to reach the final testing stage by December.</p>.<p>If the results are conclusive, Sanofi and GSK hope to get the vaccine approved in the first half of next year.</p>